Trial Profile
A Multicenter, Open-Label, Dose Escalating Study of the Safety, Tolerability and Pharmacology of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Asfotase alfa (Primary) ; Asfotase alfa (Primary)
- Indications Hypophosphatasia
- Focus Adverse reactions
- Sponsors Alexion Pharmaceuticals
- 18 Oct 2014 New trial record